Contradictory immune response in post liver transplantation hepatitis B and C

Akinobu Takaki, Takahito Yagi, Kazuhide Yamamoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hepatitis B and C often progress to decompensated liver cirrhosis requiring orthotopic liver transplantation (OLT). After OLT, hepatitis B recurrence is clinically controlled with a combination of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues. Another approach is to induce self-producing anti-hepatitis B virus (HBV) antibodies using a HBV envelope antigen vaccine. Patients who had not been HBV carriers such as acutely infected liver failure or who received liver from HBV self-limited donor are good candidate. For chronic HBV carrier patients, a successful response can only be achieved in selected patients such as those treated with experimentally reduced immunosuppression protocols or received an anti-HBV adaptive memory carrying donor liver. Hepatitis C virus (HCV) reinfects transplanted livers at a rate of >90%. HCV reinfected patients show different severities of hepatitis, from mild and slowly progressing to severe and rapidly progressing, possibly resulting from different adaptive immune responses. More than half the patients require interferon treatment, although the success rate is low and carries risks for leukocytopenia and rejection. Managing the immune response has an important role in controlling recurrent hepatitis C. This study aimed to review the adaptive immune response in post-OLT hepatitis B and C.

Original languageEnglish
Article number814760
JournalInternational Journal of Inflammation
Volume2014
DOIs
Publication statusPublished - 2014

Fingerprint

Hepatitis C
Hepatitis B
Hepatitis B virus
Liver Transplantation
Adaptive Immunity
Hepacivirus
Liver
Tissue Donors
Hepatitis B Antibodies
Chronic Hepatitis B
Liver Failure
Leukopenia
Liver Cirrhosis
Immunosuppression
Interferons
Hepatitis
Immunoglobulins
Vaccines
Antigens
Recurrence

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Contradictory immune response in post liver transplantation hepatitis B and C. / Takaki, Akinobu; Yagi, Takahito; Yamamoto, Kazuhide.

In: International Journal of Inflammation, Vol. 2014, 814760, 2014.

Research output: Contribution to journalArticle

@article{395bbd1e9d7a4e51a9458f7d5e99b2a3,
title = "Contradictory immune response in post liver transplantation hepatitis B and C",
abstract = "Hepatitis B and C often progress to decompensated liver cirrhosis requiring orthotopic liver transplantation (OLT). After OLT, hepatitis B recurrence is clinically controlled with a combination of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues. Another approach is to induce self-producing anti-hepatitis B virus (HBV) antibodies using a HBV envelope antigen vaccine. Patients who had not been HBV carriers such as acutely infected liver failure or who received liver from HBV self-limited donor are good candidate. For chronic HBV carrier patients, a successful response can only be achieved in selected patients such as those treated with experimentally reduced immunosuppression protocols or received an anti-HBV adaptive memory carrying donor liver. Hepatitis C virus (HCV) reinfects transplanted livers at a rate of >90{\%}. HCV reinfected patients show different severities of hepatitis, from mild and slowly progressing to severe and rapidly progressing, possibly resulting from different adaptive immune responses. More than half the patients require interferon treatment, although the success rate is low and carries risks for leukocytopenia and rejection. Managing the immune response has an important role in controlling recurrent hepatitis C. This study aimed to review the adaptive immune response in post-OLT hepatitis B and C.",
author = "Akinobu Takaki and Takahito Yagi and Kazuhide Yamamoto",
year = "2014",
doi = "10.1155/2014/814760",
language = "English",
volume = "2014",
journal = "International Journal of Inflammation",
issn = "2090-8040",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Contradictory immune response in post liver transplantation hepatitis B and C

AU - Takaki, Akinobu

AU - Yagi, Takahito

AU - Yamamoto, Kazuhide

PY - 2014

Y1 - 2014

N2 - Hepatitis B and C often progress to decompensated liver cirrhosis requiring orthotopic liver transplantation (OLT). After OLT, hepatitis B recurrence is clinically controlled with a combination of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues. Another approach is to induce self-producing anti-hepatitis B virus (HBV) antibodies using a HBV envelope antigen vaccine. Patients who had not been HBV carriers such as acutely infected liver failure or who received liver from HBV self-limited donor are good candidate. For chronic HBV carrier patients, a successful response can only be achieved in selected patients such as those treated with experimentally reduced immunosuppression protocols or received an anti-HBV adaptive memory carrying donor liver. Hepatitis C virus (HCV) reinfects transplanted livers at a rate of >90%. HCV reinfected patients show different severities of hepatitis, from mild and slowly progressing to severe and rapidly progressing, possibly resulting from different adaptive immune responses. More than half the patients require interferon treatment, although the success rate is low and carries risks for leukocytopenia and rejection. Managing the immune response has an important role in controlling recurrent hepatitis C. This study aimed to review the adaptive immune response in post-OLT hepatitis B and C.

AB - Hepatitis B and C often progress to decompensated liver cirrhosis requiring orthotopic liver transplantation (OLT). After OLT, hepatitis B recurrence is clinically controlled with a combination of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues. Another approach is to induce self-producing anti-hepatitis B virus (HBV) antibodies using a HBV envelope antigen vaccine. Patients who had not been HBV carriers such as acutely infected liver failure or who received liver from HBV self-limited donor are good candidate. For chronic HBV carrier patients, a successful response can only be achieved in selected patients such as those treated with experimentally reduced immunosuppression protocols or received an anti-HBV adaptive memory carrying donor liver. Hepatitis C virus (HCV) reinfects transplanted livers at a rate of >90%. HCV reinfected patients show different severities of hepatitis, from mild and slowly progressing to severe and rapidly progressing, possibly resulting from different adaptive immune responses. More than half the patients require interferon treatment, although the success rate is low and carries risks for leukocytopenia and rejection. Managing the immune response has an important role in controlling recurrent hepatitis C. This study aimed to review the adaptive immune response in post-OLT hepatitis B and C.

UR - http://www.scopus.com/inward/record.url?scp=84935029541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935029541&partnerID=8YFLogxK

U2 - 10.1155/2014/814760

DO - 10.1155/2014/814760

M3 - Article

AN - SCOPUS:84935029541

VL - 2014

JO - International Journal of Inflammation

JF - International Journal of Inflammation

SN - 2090-8040

M1 - 814760

ER -